HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account
What's Coming in 2021 in Multiple Myeloma with Robert Orlowski, MD, PhD, MD Anderson Cancer Center
What's Coming in 2021 in Multiple Myeloma with Robert Orlowski, MD, PhD, MD Anderson Cancer Center image
HealthTree Podcast for Multiple Myeloma
event Jan 22, 2021 / 11:00AM - 12:00PM MST

Event Description

Robert Z. Orlowski, MD, PhD
MD Anderson Cancer Center
Interview Date: January 22, 2021

The myeloma landscape is ever growing with more therapies coming to the clinic. In this exciting review. Dr. Orlowski shares new treatments for patients with MGUS and smoldering myeloma, newly diagnosed multiple myeloma and relapsed multiple myeloma, covering a wide variety of treatment types and combinations. He shares the immunotherapies such as bi-specific antibodies, antibody drug conjugates and CAR T treatments, targeted therapies like venetoclax and selinexor and new treatments coming up for approval including melflufen and new tools to combat high risk disease like del17p.  This show is a favorite of the year and gives myeloma patients hope that such exciting development is in progress. 

Thanks to our episode sponsor

Takeda Oncology

Schedule & Agenda

Dr. Robert Orlowski & Jenny Ahlstrom

Speakers & Moderators

The panelist Robert Orlowski, MD, PhD
Robert Orlowski, MD, PhD

Robert Z. Orlowski, M.D., Ph.D., is Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, where he is board-certified in medical oncology. Dr. Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the Yale University School of Medicine. He completed his internship and residency in Internal Medicine at Barnes Hospital at the Washington University in St. Louis School of Medicine. After his fellowships in Hematology and Medical Oncology at John Hopkins Sidney Kimmel Comprehensive Cancer Center, he joined the faculty at University of North Carolina in Chapel Hill. Following that, Dr. Orlowski accepted a position at The University of Texas MD Anderson Cancer Center in 2007 to lead the Myeloma Section in the Department of Lymphoma/Myeloma. His research interests include pathobiology of, novel therapeutic targets and mechanisms of drug resistance in myeloma which are documented in hundreds of scientific articles, book chapters, and presentations at conferences. Dr. Orlowski is an investigator on numerous clinical trials, and appointed Myeloma Committee Chair for SWOG.

Read Bio
The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.


Get In Touch With Us


+1 800 709 1113


Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube